Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford, in a new industry partnership with Axol Bioscience of Cambridge, have secured funding from the BBSRC to collaborate in creating human models of the cerebellum with induced pluripotent stem cells (iPSCs) for studies of neurological disorders.

Human iPSC-derived neurons in culture. Image courtesy of Esther Becker

Neurological disorder-associated deaths have increased by 39% in the UK since 200, with over 10 million people living with a neurological condition that has a significant impact on their lives. Due to a lack of translatable models that provide an accurate basis to study neurological disorders in humans, developing new treatments and therapies for these conditions is challenging. However, this could soon change.

“This [collaboration] allows us for the first time to study developing human nerve cells in the laboratory and to coax them into forming a brain-like structure. In our case, we plan to instruct the human iPSCs to organize into a cerebellum-like tissue”, explained Esther Becker, Associate Professor in Neurobiology at the University of Oxford.

“I’m very excited to be working together with Axol on this project. It will allow us to take advantage of their expertise in the iPSC field and it will accelerate the future applications of our research”, said Professor Becker.

Professor Becker made the BBSRC joint-funding application earlier this year after being introduced to Axol Bioscience, a biotech firm who specialise in human cell culture technologies, through IN-PART’s matchmaking platform for university-industry collaboration.

The Oxford-Axol collaboration has been awarded BBSRC funding in the form of an iCASE studentship, a joint-managed PhD project that will develop a reproducible method for generating specific and mature subpopulations of human cerebellar neurons in the lab.

“This research is of great value to the scientific community as there is a need for relevant translatable models in which to test and develop drugs for CNS [central nervous system] disorders”, said Yichen Shi, CEO and Co-founder of Axol Bioscience.

“Current models that are used during drug development tend to be immortalized cell lines or animals, both of which do not fully represent human cell phenotypes or disease”, added Yichen.

The majority of new candidate drugs developed to treat neurological disorders fail in Phase II and III clinical trials, with very few making it to Phase IV approval.

What’s more, in recent years there have been significant project shutdowns and facility closures in the neuroscience wings of the pharmaceutical industry. This is thought to be due to safety issues, low success rates, and increasing R&D costs.

The goal of the Oxford-Axol collaboration will be to model aspects of human cerebellar development that could in the future be used as platforms for the screening of future therapeutic treatments. The OxfordAxol researchers will carry out extensive studies into brain development, as well as the molecular and cellular processes that go wrong in central nervous system diseases.

“It’s fantastic to see that the iCASE studentship was awarded. I look forward to seeing how the project develops and hope this is the start of a great relationship between the two institutes,” said Dr. Siobhan Dennis, Industry Partnerships Manager at the University of Oxford.

“This was a completely new interaction and one that would not have occurred without the project being presented on IN-PART”, added Dr. Dennis.

The successful PhD candidate will benefit from the Oxford Interdisciplinary Bioscience Doctoral Training Partnership (DTP) core skills and career development training while spending time in the Becker lab and during their industrial placement at Axol Bioscience’s labs in Cambridge.

Article and image credit: Alex Stockham, IN PART Communications Manager 

For further information or to find out how to engage with IN PART, please contact Dr Siobhan Dennis (siobhan.dennis@medsci.ox.ac.uk)

Similar stories

Oxford spinout trials revolutionary bioelectronic implant to treat incontinence

The first participants in a clinical trial of a bioelectrical therapy to treat incontinence have received their “smart” bioelectronic implants.

Significant scale-up investment for three Oxford spinouts

Three University of Oxford spinouts have raised significant investment to scale their companies in vehicle automation, quantum computing and medical imaging respectively.

Oxford Innovation Society celebrates pioneering biomedical research and innovation

Last month the Oxford Innovation Society (OIS) hosted an event at Pembroke College which celebrated some of the pioneering translational research and innovation coming out of the University’s Medical Sciences Division.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from UK research institutions.